WO2003051273A2 - Dermal cholic acid as anti-inflammatory and theraputic agent - Google Patents
Dermal cholic acid as anti-inflammatory and theraputic agent Download PDFInfo
- Publication number
- WO2003051273A2 WO2003051273A2 PCT/SD2002/000002 SD0200002W WO03051273A2 WO 2003051273 A2 WO2003051273 A2 WO 2003051273A2 SD 0200002 W SD0200002 W SD 0200002W WO 03051273 A2 WO03051273 A2 WO 03051273A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cholic acid
- inflammatory
- dermal
- albumin
- theraputic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
Definitions
- the invention relates to theraputic activities of steroids.
- albumin half-life time was reduced and its daily synthesis increased (l) .
- Capillary permeability is also increased (2) .
- the later event might promote plasma proteins extravasation with important metabolic consequences, among which is activation of nicotinamide deamidase by albumin (3) .
- cortisone a corticosteroid
- the anti-inflammatory action of cortisone might be well related to the effects of cortisone on albumin metabolism as it increased albumin turnover (4) , stimulated albumin synthesis and caused a shift of extravascular exchangeable albumin into the plasma (5) .
- Cortisone suppressed mucopolysacharide formation (6) , probably via increasing intravascular albumin availability, thus probably diminishing albumin extravasation via decreased capillary permeability to plasma proteins (7) .
- Pure cholic acid (NZP, Newzealand) was suspended in vaseline base, The product was topically applied to eleven volunteers with painful swellen joints of different aetiological origins i.e traumatic and connective tissue disease. The product was also applied to nine volunteers with different clinical grades of haemorrhoids. The twenty patients, as well as the clinical examination, showed progressive improvement within three days of treatment.
- Nicotinamide deamidase from mammalian liver J. Biol. Chem. 244,
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2002339783A AU2002339783A1 (en) | 2001-10-22 | 2002-10-08 | Dermal cholic acid as anti-inflammatory and theraputic agent |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SD1115/01 | 2001-10-22 | ||
SD111501 | 2001-10-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003051273A2 true WO2003051273A2 (en) | 2003-06-26 |
Family
ID=20255908
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/SD2002/000002 WO2003051273A2 (en) | 2001-10-22 | 2002-10-08 | Dermal cholic acid as anti-inflammatory and theraputic agent |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2002339783A1 (en) |
WO (1) | WO2003051273A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008140262A3 (en) * | 2007-05-14 | 2008-12-31 | Seoul Nat Univ Ind Foundation | Use of biological surfactant as anti -inflammatory agent and tissue preservative solution. |
-
2002
- 2002-10-08 AU AU2002339783A patent/AU2002339783A1/en not_active Abandoned
- 2002-10-08 WO PCT/SD2002/000002 patent/WO2003051273A2/en not_active Application Discontinuation
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008140262A3 (en) * | 2007-05-14 | 2008-12-31 | Seoul Nat Univ Ind Foundation | Use of biological surfactant as anti -inflammatory agent and tissue preservative solution. |
EP2152279A2 (en) * | 2007-05-14 | 2010-02-17 | Seoul National University Industry Foundation | Use of biological surfactant as anti -inflammatory agent and tissue preservative solution. |
JP2010536716A (en) * | 2007-05-14 | 2010-12-02 | ソウル ナショナル ユニヴァーシティー インダストリー ファンデーション | Use of biological surfactants as anti-inflammatory agents and tissue preservation solutions |
EP2152279A4 (en) * | 2007-05-14 | 2012-04-04 | Seoul Nat Univ Ind Foundation | Use of biological surfactant as anti -inflammatory agent and tissue preservative solution. |
Also Published As
Publication number | Publication date |
---|---|
AU2002339783A1 (en) | 2003-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5874444A (en) | Poly (ADP-ribose) polymerase inhibitors to treat diseases associated with cellular senescence | |
Melmon et al. | Interaction of plasma kinins and granulocytes | |
EP1381357B1 (en) | Glycyrrhetinic acid derivatives and their use for the manufacture of a medicament to inhibit 11beta-hydroxysteroid dehydrogenase activity | |
Soffer et al. | Corticotropin and cortisone in acute disseminated lupus erythematosus: Results of long-term use | |
US20080279820A1 (en) | Compositions and Methods for Treating Burns | |
US6537968B1 (en) | Treatment of lupus erythematosus | |
EP1024802A4 (en) | (3$i(R),4$i(R))-$g(D)-TETRAHYDROCANNABINOL-11-OIC ACIDS USEFUL AS ANTIINFLAMMATORY AGENTS AND ANALGESICS | |
US6126947A (en) | Method for the treatment of skin disorders using inhibitor of cholesterol synthesis | |
EP1653974B1 (en) | Enhancement of activity and/or duration of action of soft anti-inflammatory steroids for topical or other local application | |
MA27431A1 (en) | PYRIMIDINONE DERIVATIVES FOR USE AS THERAPEUTIC AGENTS AGAINST ACUTE AND CHRONIC INFLAMMATORY ISCHEMIC AND INFLAMMATORY PROCESSES | |
EP0738152A1 (en) | Use of 2-hydroxy-5-phenylazobenzoic acid derivatives as colon cancer chemopreventative and chemotherapeutic agents | |
HUP9900887A2 (en) | Novel nor-pregnanes for inducing hypothalamic effects, thear production and medicaments containing them | |
WO1994018936A1 (en) | Compositions and methods for promoting hair growth | |
JP2001505221A (en) | Compound | |
EP0774255B1 (en) | Use of ursolic acid for the manufacture of a medicament for suppressing metastasis | |
US5459153A (en) | Composition and methods for treatment of acne vulgaris and for retardation of aging | |
WO2000037071A1 (en) | Topical treatment of skin disease | |
WO2003051273A2 (en) | Dermal cholic acid as anti-inflammatory and theraputic agent | |
PT1604991E (en) | Antitumor effect potentiator and antitumor agent | |
US5304574A (en) | Methods of treatment of clinical conditions using pantothenic acid | |
US5554593A (en) | Therapeutic agent for threatened abortion | |
US7291595B2 (en) | Use of Alpha-1 antitrypsin for the preparation of medicaments for the treatment of fibromyalgia | |
EP1123100B1 (en) | Improving memory by the administration of delta 5-androstene-3 beta-ol-7,17-dione and 3 beta esters thereof | |
Ashby et al. | Case report: acquired dysfibrinogenemia secondary to mithramycin toxicity | |
BR9917006A (en) | liposomal niflumic acid - transdermal anti-inflammatory drug |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase | ||
122 | Ep: pct application non-entry in european phase | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase in: |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |